Skip to main content
Erschienen in: World Journal of Urology 6/2020

29.08.2019 | Original Article

Necessity of differentiating small (< 10 mm) and large (≥ 10 mm) PI-RADS 4

verfasst von: Sung Yoon Park, Byung Kwan Park

Erschienen in: World Journal of Urology | Ausgabe 6/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Prostate Imaging Reporting and Data System version 2 (PI-RADSv2) provides reasonable performance in detecting significant cancers. Still, it is unclear about whether all PI-RADS 4 lesions show the same cancer detection rate (CDR) regardless of tumor size. The aim was to compare the CDRs of small (< 10 mm) and large (≥ 10 mm) PI-RADS 4.

Methods

After magnetic resonance imaging (MRI) was performed in 684 men, a radiologist interpreted the MR images and detected 281 index lesions categorized as PI-RADS 4 in 281 men. PI-RADS 4 lesions were divided into small and large groups on size of 10 mm. Overall and significant CDRs were compared between the groups. A significant cancer was defined as one with Gleason score (GS) ≥ 7 or tumor volume ≥ 0.5 ml. Tumor volumes were roughly calculated as πr34/3 (π = 3.14 and r = a half of tumor size) and were compared between the groups. Standard reference was a biopsy examination. Fisher’s exact and Mann–Whitney tests were used for statistical analysis.

Results

The overall CDRs of small and large groups were 39.0% (53/136) and 59.3% (86/145), respectively, (p = 0.0008). The median tumor volumes of cancer-proven small and large groups were 0.18 ml (0.01–0.38 ml) and 0.70 ml (0.52–1.44 ml), respectively (p < 0.0001). Using GS or tumor volume, the significant CDRs of these groups were 26.5% (36/136) and 59.3% (86/145), respectively (p < 0.0001), and using GS alone, 26.5% (36/136) and 39.3% (57/145), respectively (p = 0.0232).

Conclusions

PI-RADS 4 lesions should be sub-divided on size of 10 mm because of different significant CDRs.
Literatur
1.
Zurück zum Zitat Weinreb JC, Barentsz JO, Choyke PL, Cornud F, Haider MA, Macura KJ, Margolis D, Schnall MD, Shtern F, Tempany CM, Thoeny HC, Verma S (2016) PI-RADS prostate imaging—reporting and data system: 2015, version 2. Eur Urol 69:16–40CrossRef Weinreb JC, Barentsz JO, Choyke PL, Cornud F, Haider MA, Macura KJ, Margolis D, Schnall MD, Shtern F, Tempany CM, Thoeny HC, Verma S (2016) PI-RADS prostate imaging—reporting and data system: 2015, version 2. Eur Urol 69:16–40CrossRef
2.
Zurück zum Zitat Barentsz JO, Weinreb JC, Verma S, Thoeny HC, Tempany CM, Shtern F, Padhani AR, Margolis D, Macura KJ, Haider MA, Cornud F, Choyke PL (2016) Synopsis of the PI-RADS v2 guidelines for multiparametric prostate magnetic resonance imaging and recommendations for use. Eur Urol 69:41–49CrossRef Barentsz JO, Weinreb JC, Verma S, Thoeny HC, Tempany CM, Shtern F, Padhani AR, Margolis D, Macura KJ, Haider MA, Cornud F, Choyke PL (2016) Synopsis of the PI-RADS v2 guidelines for multiparametric prostate magnetic resonance imaging and recommendations for use. Eur Urol 69:41–49CrossRef
3.
Zurück zum Zitat Purysko AS, Rosenkrantz AB, Barentsz JO, Weinreb JC, Macura KJ (2016) PI-RADS version 2: a pictorial update. Radiographics 36:1354–1372CrossRef Purysko AS, Rosenkrantz AB, Barentsz JO, Weinreb JC, Macura KJ (2016) PI-RADS version 2: a pictorial update. Radiographics 36:1354–1372CrossRef
4.
Zurück zum Zitat Greer MD, Shih JH, Lay N, Barrett T, Kayat Bittencourt L, Borofsky S, Kabakus IM, Law YM, Marko J, Shebel H, Mertan FV, Merino MJ, Wood BJ, Pinto PA, Summers RM, Choyke PL, Turkbey B (2017) Validation of the dominant sequence paradigm and role of dynamic contrast-enhanced imaging in PI-RADS version 2. Radiology 285:859–869CrossRef Greer MD, Shih JH, Lay N, Barrett T, Kayat Bittencourt L, Borofsky S, Kabakus IM, Law YM, Marko J, Shebel H, Mertan FV, Merino MJ, Wood BJ, Pinto PA, Summers RM, Choyke PL, Turkbey B (2017) Validation of the dominant sequence paradigm and role of dynamic contrast-enhanced imaging in PI-RADS version 2. Radiology 285:859–869CrossRef
5.
Zurück zum Zitat Hofbauer SL, Maxeiner A, Kittner B, Heckmann R, Reimann M, Wiemer L, Asbach P, Haas M, Penzkofer T, Stephan C, Friedersdorff F, Fuller F, Miller K, Cash H (2018) Validation of prostate imaging reporting and data system version 2 for the detection of prostate cancer. J Urol 200:767–773CrossRef Hofbauer SL, Maxeiner A, Kittner B, Heckmann R, Reimann M, Wiemer L, Asbach P, Haas M, Penzkofer T, Stephan C, Friedersdorff F, Fuller F, Miller K, Cash H (2018) Validation of prostate imaging reporting and data system version 2 for the detection of prostate cancer. J Urol 200:767–773CrossRef
6.
Zurück zum Zitat Mehralivand S, Bednarova S, Shih JH, Mertan FV, Gaur S, Merino MJ, Wood BJ, Pinto PA, Choyke PL, Turkbey B (2017) Prospective evaluation of PI-RADS version 2 using the international society of urological pathology prostate cancer grade group system. J Urol 198:583–590CrossRef Mehralivand S, Bednarova S, Shih JH, Mertan FV, Gaur S, Merino MJ, Wood BJ, Pinto PA, Choyke PL, Turkbey B (2017) Prospective evaluation of PI-RADS version 2 using the international society of urological pathology prostate cancer grade group system. J Urol 198:583–590CrossRef
7.
Zurück zum Zitat Park SY, Jung DC, Oh YT, Cho NH, Choi YD, Rha KH, Hong SJ, Han K (2016) Prostate cancer: PI-RADS version 2 helps preoperatively predict clinically significant cancers. Radiology 280:108–116CrossRef Park SY, Jung DC, Oh YT, Cho NH, Choi YD, Rha KH, Hong SJ, Han K (2016) Prostate cancer: PI-RADS version 2 helps preoperatively predict clinically significant cancers. Radiology 280:108–116CrossRef
8.
Zurück zum Zitat Tan N, Lin WC, Khoshnoodi P, Asvadi NH, Yoshida J, Margolis DJ, Lu DS, Wu H, Sung KH, Lu DY, Huang J, Raman SS (2017) In-Bore 3-T MR-guided transrectal targeted prostate biopsy: prostate imaging reporting and data system version 2-based diagnostic performance for detection of prostate cancer. Radiology 283:130–139CrossRef Tan N, Lin WC, Khoshnoodi P, Asvadi NH, Yoshida J, Margolis DJ, Lu DS, Wu H, Sung KH, Lu DY, Huang J, Raman SS (2017) In-Bore 3-T MR-guided transrectal targeted prostate biopsy: prostate imaging reporting and data system version 2-based diagnostic performance for detection of prostate cancer. Radiology 283:130–139CrossRef
9.
Zurück zum Zitat Thai JN, Narayanan HA, George AK, Siddiqui MM, Shah P, Mertan FV, Merino MJ, Pinto PA, Choyke PL, Wood BJ, Turkbey B (2018) Validation of PI-RADS version 2 in transition zone lesions for the detection of prostate cancer. Radiology 288:485–491CrossRef Thai JN, Narayanan HA, George AK, Siddiqui MM, Shah P, Mertan FV, Merino MJ, Pinto PA, Choyke PL, Wood BJ, Turkbey B (2018) Validation of PI-RADS version 2 in transition zone lesions for the detection of prostate cancer. Radiology 288:485–491CrossRef
10.
Zurück zum Zitat Rosenkrantz AB, Babb JS, Taneja SS, Ream JM (2017) Proposed adjustments to PI-RADS version 2 decision rules: impact on prostate cancer detection. Radiology 283:119–129CrossRef Rosenkrantz AB, Babb JS, Taneja SS, Ream JM (2017) Proposed adjustments to PI-RADS version 2 decision rules: impact on prostate cancer detection. Radiology 283:119–129CrossRef
11.
Zurück zum Zitat Epstein JI, Walsh PC, Carmichael M, Brendler CB (1994) Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 271:368–374CrossRef Epstein JI, Walsh PC, Carmichael M, Brendler CB (1994) Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 271:368–374CrossRef
12.
Zurück zum Zitat Epstein JI, Walsh PC, Brendler CB (1994) Radical prostatectomy for impalpable prostate cancer: the Johns Hopkins experience with tumors found on transurethral resection (stages T1A and T1B) and on needle biopsy (stage T1C). J Urol 152:1721–1729CrossRef Epstein JI, Walsh PC, Brendler CB (1994) Radical prostatectomy for impalpable prostate cancer: the Johns Hopkins experience with tumors found on transurethral resection (stages T1A and T1B) and on needle biopsy (stage T1C). J Urol 152:1721–1729CrossRef
13.
Zurück zum Zitat Jack GS, Cookson MS, Coffey CS, Vader V, Roberts RL, Chang SS, Smith JA Jr, Shappell SB (2002) Pathological parameters of radical prostatectomy for clinical stages T1c versus T2 prostate adenocarcinoma: decreased pathological stage and increased detection of transition zone tumors. J Urol 168:519–524CrossRef Jack GS, Cookson MS, Coffey CS, Vader V, Roberts RL, Chang SS, Smith JA Jr, Shappell SB (2002) Pathological parameters of radical prostatectomy for clinical stages T1c versus T2 prostate adenocarcinoma: decreased pathological stage and increased detection of transition zone tumors. J Urol 168:519–524CrossRef
14.
Zurück zum Zitat Bastian PJ, Mangold LA, Epstein JI, Partin AW (2004) Characteristics of insignificant clinical T1c prostate tumors. A contemporary analysis. Cancer 101:2001–2005CrossRef Bastian PJ, Mangold LA, Epstein JI, Partin AW (2004) Characteristics of insignificant clinical T1c prostate tumors. A contemporary analysis. Cancer 101:2001–2005CrossRef
15.
Zurück zum Zitat Jeldres C, Suardi N, Walz J, Hutterer GC, Ahyai S, Lattouf JB, Haese A, Graefen M, Erbersdobler A, Heinzer H, Huland H, Karakiewicz PI (2008) Validation of the contemporary epstein criteria for insignificant prostate cancer in European men. Eur Urol 54:1306–1313CrossRef Jeldres C, Suardi N, Walz J, Hutterer GC, Ahyai S, Lattouf JB, Haese A, Graefen M, Erbersdobler A, Heinzer H, Huland H, Karakiewicz PI (2008) Validation of the contemporary epstein criteria for insignificant prostate cancer in European men. Eur Urol 54:1306–1313CrossRef
16.
Zurück zum Zitat Oon SF, Watson RW, O’Leary JJ, Fitzpatrick JM (2011) Epstein criteria for insignificant prostate cancer. BJU Int 108:518–525CrossRef Oon SF, Watson RW, O’Leary JJ, Fitzpatrick JM (2011) Epstein criteria for insignificant prostate cancer. BJU Int 108:518–525CrossRef
17.
Zurück zum Zitat Lee SE, Kim DS, Lee WK, Park HZ, Lee CJ, Doo SH, Jeong SJ, Yoon CY, Byun SS, Choe G, Hwang SI, Lee HJ, Hong SK (2010) Application of the Epstein criteria for prediction of clinically insignificant prostate cancer in Korean men. BJU Int 105:1526–1530CrossRef Lee SE, Kim DS, Lee WK, Park HZ, Lee CJ, Doo SH, Jeong SJ, Yoon CY, Byun SS, Choe G, Hwang SI, Lee HJ, Hong SK (2010) Application of the Epstein criteria for prediction of clinically insignificant prostate cancer in Korean men. BJU Int 105:1526–1530CrossRef
18.
Zurück zum Zitat Hong SK, Na W, Park JM, Byun SS, Oh JJ, Nam JS, Jeong CW, Choe G, Lee HJ, Hwang SI, Lee SE (2011) Prediction of pathological outcomes for a single microfocal (</=3 mm) Gleason 6 prostate cancer detected via contemporary multicore (>/=12) biopsy in men with prostate-specific antigen </=10 ng/mL. BJU Int 108:1101–1105CrossRef Hong SK, Na W, Park JM, Byun SS, Oh JJ, Nam JS, Jeong CW, Choe G, Lee HJ, Hwang SI, Lee SE (2011) Prediction of pathological outcomes for a single microfocal (</=3 mm) Gleason 6 prostate cancer detected via contemporary multicore (>/=12) biopsy in men with prostate-specific antigen </=10 ng/mL. BJU Int 108:1101–1105CrossRef
19.
Zurück zum Zitat Chondros K, Karpathakis N, Heretis I, Mavromanolakis E, Chondros N, Sofras F, Mamoulakis C (2015) Validation of revised Epstein’s criteria for insignificant prostate cancer prediction in a Greek subpopulation. Hippokratia 19:30–33PubMedPubMedCentral Chondros K, Karpathakis N, Heretis I, Mavromanolakis E, Chondros N, Sofras F, Mamoulakis C (2015) Validation of revised Epstein’s criteria for insignificant prostate cancer prediction in a Greek subpopulation. Hippokratia 19:30–33PubMedPubMedCentral
20.
Zurück zum Zitat Barentsz JO, Richenberg J, Clements R, Choyke P, Verma S, Villeirs G, Rouviere O, Logager V, Futterer JJ (2012) ESUR prostate MR guidelines 2012. Eur Radiol 22:746–757CrossRef Barentsz JO, Richenberg J, Clements R, Choyke P, Verma S, Villeirs G, Rouviere O, Logager V, Futterer JJ (2012) ESUR prostate MR guidelines 2012. Eur Radiol 22:746–757CrossRef
21.
Zurück zum Zitat Bratan F, Niaf E, Melodelima C, Chesnais AL, Souchon R, Mege-Lechevallier F, Colombel M, Rouviere O (2013) Influence of imaging and histological factors on prostate cancer detection and localisation on multiparametric MRI: a prospective study. Eur Radiol 23:2019–2029CrossRef Bratan F, Niaf E, Melodelima C, Chesnais AL, Souchon R, Mege-Lechevallier F, Colombel M, Rouviere O (2013) Influence of imaging and histological factors on prostate cancer detection and localisation on multiparametric MRI: a prospective study. Eur Radiol 23:2019–2029CrossRef
22.
Zurück zum Zitat Mottet N, van den Bergh RCN, Briers E, Bourke L, Cornford P, De Santis M, De Santis M, Gillessen S, Govorov A, Grummet J, Henry AM, Lam TB, Mason MD, van der Poel HG, van der Kwast TH, Rouvière O, Wiegel T, van denBroeck T, Cumberbatch M, Fossati N, Gross T, Lardas M, Liew M, Moris L, Schoots IG, Willemse PM (2019) EAU—ESTRO—ESUR—SIOG guidelines on prostate cancer https://uroweb.org/guidelines/2019 Mottet N, van den Bergh RCN, Briers E, Bourke L, Cornford P, De Santis M, De Santis M, Gillessen S, Govorov A, Grummet J, Henry AM, Lam TB, Mason MD, van der Poel HG, van der Kwast TH, Rouvière O, Wiegel T, van denBroeck T, Cumberbatch M, Fossati N, Gross T, Lardas M, Liew M, Moris L, Schoots IG, Willemse PM (2019) EAU—ESTRO—ESUR—SIOG guidelines on prostate cancer https://​uroweb.​org/​guidelines/​2019
23.
Zurück zum Zitat van den Bergh RC, Roemeling S, Roobol MJ, Roobol W, Schroder FH, Bangma CH (2007) Prospective validation of active surveillance in prostate cancer: the PRIAS study. Eur Urol 52:1560–1563CrossRef van den Bergh RC, Roemeling S, Roobol MJ, Roobol W, Schroder FH, Bangma CH (2007) Prospective validation of active surveillance in prostate cancer: the PRIAS study. Eur Urol 52:1560–1563CrossRef
24.
Zurück zum Zitat Rais-Bahrami S, Siddiqui MM, Vourganti S, Turkbey B, Rastinehad AR, Stamatakis L, Truong H, Walton-Diaz A, Hoang AN, Nix JW, Merino MJ, Wood BJ, Simon RM, Choyke PL, Pinto PA (2015) Diagnostic value of biparametric magnetic resonance imaging (MRI) as an adjunct to prostate-specific antigen (PSA)-based detection of prostate cancer in men without prior biopsies. BJU Int 115:381–388CrossRef Rais-Bahrami S, Siddiqui MM, Vourganti S, Turkbey B, Rastinehad AR, Stamatakis L, Truong H, Walton-Diaz A, Hoang AN, Nix JW, Merino MJ, Wood BJ, Simon RM, Choyke PL, Pinto PA (2015) Diagnostic value of biparametric magnetic resonance imaging (MRI) as an adjunct to prostate-specific antigen (PSA)-based detection of prostate cancer in men without prior biopsies. BJU Int 115:381–388CrossRef
25.
Zurück zum Zitat Radtke JP, Boxler S, Kuru TH, Wolf MB, Alt CD, Popeneciu IV, Steinemann S, Huettenbrink C, Bergstraesser-Gasch C, Klein T, Kesch C, Roethke M, Becker N, Roth W, Schlemmer HP, Hohenfellner M, Hadaschik BA (2015) Improved detection of anterior fibromuscular stroma and transition zone prostate cancer using biparametric and multiparametric MRI with MRI-targeted biopsy and MRI-US fusion guidance. Prostate Cancer Prostatic Dis 18:288–296CrossRef Radtke JP, Boxler S, Kuru TH, Wolf MB, Alt CD, Popeneciu IV, Steinemann S, Huettenbrink C, Bergstraesser-Gasch C, Klein T, Kesch C, Roethke M, Becker N, Roth W, Schlemmer HP, Hohenfellner M, Hadaschik BA (2015) Improved detection of anterior fibromuscular stroma and transition zone prostate cancer using biparametric and multiparametric MRI with MRI-targeted biopsy and MRI-US fusion guidance. Prostate Cancer Prostatic Dis 18:288–296CrossRef
26.
Zurück zum Zitat Fascelli M, Rais-Bahrami S, Sankineni S, Brown AM, George AK, Ho R, Frye T, Kilchevsky A, Chelluri R, Abboud S, Siddiqui MM, Merino MJ, Wood BJ, Choyke PL, Pinto PA, Turkbey B (2016) Combined biparametric prostate magnetic resonance imaging and prostate-specific antigen in the detection of prostate cancer: a validation study in a biopsy-naive patient population. Urology 88:125–134CrossRef Fascelli M, Rais-Bahrami S, Sankineni S, Brown AM, George AK, Ho R, Frye T, Kilchevsky A, Chelluri R, Abboud S, Siddiqui MM, Merino MJ, Wood BJ, Choyke PL, Pinto PA, Turkbey B (2016) Combined biparametric prostate magnetic resonance imaging and prostate-specific antigen in the detection of prostate cancer: a validation study in a biopsy-naive patient population. Urology 88:125–134CrossRef
27.
Zurück zum Zitat Kuhl CK, Bruhn R, Kramer N, Nebelung S, Heidenreich A, Schrading S (2017) Abbreviated biparametric prostate MR imaging in men with elevated prostate-specific antigen. Radiology 285:493–505CrossRef Kuhl CK, Bruhn R, Kramer N, Nebelung S, Heidenreich A, Schrading S (2017) Abbreviated biparametric prostate MR imaging in men with elevated prostate-specific antigen. Radiology 285:493–505CrossRef
28.
Zurück zum Zitat Kang Z, Min X, Weinreb J, Li Q, Feng Z, Wang L (2018) Abbreviated biparametric versus standard multiparametric MRI for diagnosis of prostate cancer: a systematic review and meta-analysis. AJR Am J Roentgenol 212:W1–W9 Kang Z, Min X, Weinreb J, Li Q, Feng Z, Wang L (2018) Abbreviated biparametric versus standard multiparametric MRI for diagnosis of prostate cancer: a systematic review and meta-analysis. AJR Am J Roentgenol 212:W1–W9
Metadaten
Titel
Necessity of differentiating small (< 10 mm) and large (≥ 10 mm) PI-RADS 4
verfasst von
Sung Yoon Park
Byung Kwan Park
Publikationsdatum
29.08.2019
Verlag
Springer Berlin Heidelberg
Erschienen in
World Journal of Urology / Ausgabe 6/2020
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI
https://doi.org/10.1007/s00345-019-02924-2

Weitere Artikel der Ausgabe 6/2020

World Journal of Urology 6/2020 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

Stufenschema weist Prostatakarzinom zuverlässig nach

22.04.2024 Prostatakarzinom Nachrichten

Erst PSA-Test, dann Kallikrein-Score, schließlich MRT und Biopsie – ein vierstufiges Screening-Schema kann die Zahl der unnötigen Prostatabiopsien erheblich reduzieren: Die Hälfte der Männer, die in einer finnischen Studie eine Biopsie benötigten, hatte einen hochgradigen Tumor.

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

20.04.2024 EAU 2024 Kongressbericht

Beim chronischen Harnwegsinfekt bei Frauen wird bisher meist eine Antibiotikaprophylaxe eingesetzt. Angesichts der zunehmenden Antibiotikaresistenz erweist sich das Antiseptikum Methenamin-Hippurat als vielversprechende Alternative, so die Auswertung einer randomisierten kontrollierten Studie.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.